Table 1.
Participant characteristics
| Characteristic | N = 10831 |
|---|---|
| Sex | |
| Female | 590 (55%) |
| Male | 493 (45%) |
| Age (years) | |
| 18–64 | 988 (91%) |
| 65+ | 95 (9%) |
| Infection/vaccination status at the time of most recent serological test | |
| Infected only | 634 (58%) |
| Vaccinated only | 98 (9%) |
| Infected prior to vaccination | 310 (29%) |
| Infected after vaccination | 11 (1%) |
| Infected prior to vaccination and re-infected after vaccination | 30 (3%) |
| Virological confirmation among participants with a history of infection (N = 985) | |
| Virologically confirmed infection (self-reported or from ARGOS registry) | 567 (58%) |
| No virological confirmation (anti-N positive serology only) | 418 (42%) |
| Vaccine type among vaccinated participants at the time of last serological status (N = 449) | |
| mRNA-1273 (Moderna/US NIAID) | 247 (55%) |
| mRNA-BNT162b2/Comirnaty (Pfizer/BioNTech) | 202 (45%) |
| # Positive Roche-S serological samples per participant within this study | |
| 2 | 603 (55%) |
| 3 | 374 (35%) |
| 4 | 104 (10%) |
| 5 | 1 (<0.1%) |
| 1n (%) | |
Source data are provided as a Source Data file.